Philippe Peltier

Managing Partner | Venture Capital | Heathtech, Medtech, Life Sciences Expert | Board Experience | Driving Strategic Growth & Exit Readiness in Early Stage portfolio companies

📍 Greater Paris Metropolitan Region, France🔄 Updated September 2026💼 13 investments📅 26 years investing🗓 Last invested Nov 2021𝕏 @upgrade_to_unlock
VC🌍 France
13
Total investments
2
Early stage
9
Mid stage
1
Late stage
26y
Years active

Portfolio

12 investments · sorted by recency
All investments
Early stage
Mid stage
Late stage
Non Executive Board Member
Nov 2021
Sleep is one of healthcare’s biggest blind spots. Access is slow, confusing and uneven, and millions of people who need help never get it. Sunrise exists to change that. Born from pioneering research on mandibular jaw movement, we built a chin-based sleep test that reinvented how sleep disorders can be diagnosed from home. That breakthrough has evolved into a full sleep-health platform: advanced diagnostic and treatment technology paired with clinical care delivered directly to patients’ homes through Dreem Health in all 50 U.S. states. Across the U.S. and Europe, our 100+ clinicians, engineers and operators share one mission: make high-quality sleep care accessible to everyone. Backed by more than $50M, we’re taking on one of healthcare’s biggest challenges: the 1+ billion people worldwide who still can’t get the sleep care they need.
Non Executive Board Member
Sep 2020
Lucine is part of Butterfly Therapeutics since december 2023. Lucine is an expert in women’s pelvic pain relief, and we’re on a mission to change women’s lives. We offer an evidence-based approach with scientifically proven solutions that reduce & relieve pain related to endometriosis, periods, menopause, post-partum discomfort, and more. Endocare is our clinically-tested, patented medical device that directly targets pain mechanisms with a unique combination of visual and sound frequencies Lets work together, changing womens lives !
Board Member
Oct 2018
Stilla Technologies is a leading global biotechnology company that focuses on accelerating development of next-generation genetic testing by providing researchers and clinicians with a flexible Digital PCR solution for high-resolution genetic analysis and assay development. Stilla’s next-generation Multiplex Crystal Digital PCR™ technology employs cutting-edge microfluidic innovations and integrates the entire dPCR process on a single chip. The naica® system is highly sensitive, fast, and features an easy workflow, higher levels of multiplexing, and intuitive software. Stilla developed the worlds first 6-color Digital PCR Platform, providing High Multiplexing and Sensitivity for Advancing Cancer & Liquid Biopsy Studies, Cell & Gene Therapies, Infectious Disease & COVID-19 Research, and Wastewater and Environmental Testing and many more applications. Stilla aims to make Digital PCR a lab commodity in all life sciences areas including research, therapeutics, and the omics. Visit the website and connect on Twitter @StillaTech
Board Observer
Aug 2017
FeetMe is a digital health & remote patients monitoring company developing innovative connected technologies and services to improve patient outcomes in functional care, track disease evolution, and optimize medication utilization. www.feetme.fr. The innovative technology from FeetMe allows gait and posture analysis in real-time and real-life conditions. The technology combines pressure sensors, motion sensors and learning algorithms to analyse patients’ functional capacity, as well as empower rehabilitation among sufferers of gait disorders. Find more infos about open job offers http://jobs.feetme.fr
Board Member
Aug 2017
Cardiologs is a medical technology company on a mission to democratize expert cardiac care through medical-grade artificial intelligence.
Board Member
May 2017
Sensome is an innovative start-up developing a breakthrough sensing technology that can turn invasive medical devices into connected healthcare devices. Sensome is EN ISO 13485:2016 certified.
Board Member
Mar 2017
Damae Medical is reinventing skin imaging, revolutionizing the screening, management, and follow-up of skin cancers (melanoma and carcinoma) with its deepLive™ solution, which provides an accurate, fast and reliable optical examination without performing a biopsy. CE marked, the deepLive™ medical device is based on LC-OCT (Line-field Confocal Optical Coherence Tomography) proprietary optical imaging technology that provides 3D images of the different layers of the skin at the cellular level, complemented by several software and Artificial Intelligence (AI) modules. This innovation is protected by 6 patent families and has already been published in more than 50 scientific and medical publications. Present in 10 countries and used in more than 30 referral centers, deepLive™ transforms the daily practice of dermatologists making the management of skin pathologies efficient, reassuring, and non-invasive for the patient. The product is also used by leading cosmetic and pharmaceutical players for research and evaluation purposes. Based in Paris, Damae Medical currently employs 25 people. Winner of several innovation awards (MIT Technology Review, Bpifrance, European Commission), the company has been able to invest more than €20 million since its creation in 2014. For more information, please contact us by email: info@damae-medical.com
Board Member
May 2016
DNA Script was created to revolutionize DNA synthesis with enzymes. Our core R&D efforts have produced innovations in enzyme engineering, surface and nucleotide chemistries, and instrumentation. The integration of these innovations has resulted in SYNTAX™️, the world’s first benchtop DNA printer powered by enzymatic technology. With continued advancement and innovation, we believe DNA Script’s enzymatic DNA synthesis technology is poised to become the engine of genomics research and personalized medicine.
Board Member
Nov 2015
Advanced Perfusion Diagnostics is a medical technology company based in Lyon (France), that develops, manufactures and markets innovative patient monitoring systems. The core focus of APD is to provide relevant indicators pertaining to tissue perfusion to clinicians. The recent market introduction of IKORUS® monitoring system addresses a unmet need up to now, and opens new fields of investigation for physicians, enabling early detection of microcirculatory alterations and potential improvement of current therapeutic practices.
Board Observer
Dec 2010
Genocea is harnessing the power of T cell immunity to develop life-changing vaccines and immunotherapies. While traditional immunotherapy discovery methods have largely used predictive methods to propose T cell targets, or antigens, Genocea has successfully developed ATLAS™, its proprietary technology platform, to identify clinically relevant antigens of T cells based on actual human immune responses. Genocea is currently using ATLAS in immuno-oncology applications to develop neoantigen cancer vaccines, general cancer vaccines and a vaccine targeting cancers caused by Epstein-Barr Virus.
mid stageBiotechnology
Board Observer
Aug 2000
Targacept is developing a diverse pipeline of innovative NNR Therapeutics™ for difficult-to-treat diseases and disorders of the nervous system. NNR Therapeutics selectively modulate the activity of specific neuronal nicotinic receptors, unique proteins that regulate vital biological functions that are impaired in various disease states. Targacept’s clinical pipeline includes multiple Phase 2 product candidates, all representing first-in-class opportunities. Targacept leverages its scientific leadership and diverse pipeline to attract significant collaborations with global pharmaceutical companies. For more information, please visit www.targacept.com.
Board Observer
Apr 2000
Innate Pharma S.A. is a global, clinical-stage oncology-focused biotech company dedicated to improving treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer. Innate Pharma’s broad pipeline of antibodies includes several potentially first-in-class clinical and preclinical candidates in cancers with high unmet medical need. Innate has been a pioneer in the understanding of natural killer cell (NK cell) biology and has expanded its expertise in the tumor microenvironment and tumor-antigens, as well as antibody engineering. This innovative approach has resulted in a diversified proprietary portfolio and major alliances with leaders in the biopharmaceutical industry including Bristol-Myers Squibb Novo Nordisk A/S, Sanofi, and a multi-products collaboration with AstraZeneca. Based in Marseille, France, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.
Experience · 16 entries
All (16)
Investments (13)
Board (13)
2021
Non Executive Board Member
Nov 2021
Sleep is one of healthcare’s biggest blind spots. Access is slow, confusing and uneven, and millions of people who need help never get it. Sunrise exists to change that. Born from pioneering research on mandibular jaw movement, we built a chin-based sleep test that reinvented how sleep disorders can be diagnosed from home. That breakthrough has evolved into a full sleep-health platform: advanced diagnostic and treatment technology paired with clinical care delivered directly to patients’ homes through Dreem Health in all 50 U.S. states. Across the U.S. and Europe, our 100+ clinicians, engineers and operators share one mission: make high-quality sleep care accessible to everyone. Backed by more than $50M, we’re taking on one of healthcare’s biggest challenges: the 1+ billion people worldwide who still can’t get the sleep care they need.
2020
Non Executive Board Member
Sep 2020
Lucine is part of Butterfly Therapeutics since december 2023. Lucine is an expert in women’s pelvic pain relief, and we’re on a mission to change women’s lives. We offer an evidence-based approach with scientifically proven solutions that reduce & relieve pain related to endometriosis, periods, menopause, post-partum discomfort, and more. Endocare is our clinically-tested, patented medical device that directly targets pain mechanisms with a unique combination of visual and sound frequencies Lets work together, changing womens lives !
2018
Board Member
Oct 2018
Stilla Technologies is a leading global biotechnology company that focuses on accelerating development of next-generation genetic testing by providing researchers and clinicians with a flexible Digital PCR solution for high-resolution genetic analysis and assay development. Stilla’s next-generation Multiplex Crystal Digital PCR™ technology employs cutting-edge microfluidic innovations and integrates the entire dPCR process on a single chip. The naica® system is highly sensitive, fast, and features an easy workflow, higher levels of multiplexing, and intuitive software. Stilla developed the worlds first 6-color Digital PCR Platform, providing High Multiplexing and Sensitivity for Advancing Cancer & Liquid Biopsy Studies, Cell & Gene Therapies, Infectious Disease & COVID-19 Research, and Wastewater and Environmental Testing and many more applications. Stilla aims to make Digital PCR a lab commodity in all life sciences areas including research, therapeutics, and the omics. Visit the website and connect on Twitter @StillaTech
2017
Board Observer
Aug 2017
FeetMe is a digital health & remote patients monitoring company developing innovative connected technologies and services to improve patient outcomes in functional care, track disease evolution, and optimize medication utilization. www.feetme.fr. The innovative technology from FeetMe allows gait and posture analysis in real-time and real-life conditions. The technology combines pressure sensors, motion sensors and learning algorithms to analyse patients’ functional capacity, as well as empower rehabilitation among sufferers of gait disorders. Find more infos about open job offers http://jobs.feetme.fr
Board Member
Aug 2017
Cardiologs is a medical technology company on a mission to democratize expert cardiac care through medical-grade artificial intelligence.
Show all 16 entries ↓
Investment activity
2000–2021 · 13 investments
200022010120121201512016120174201812020120211
Recent (last 2 years)Earlier